CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
随着治疗方案的逐步改进，多发性骨髓瘤（MM）患者的生存时间已显著延长。即便如此，MM仍是一种预后较差的噩梦。B细胞成熟抗原（BCMA）在恶性骨髓瘤细胞表面高表达。过去几年中，针对RRMM患者的多种BCMA靶向免疫治疗取得了重大进展，包括抗BCMA单克隆抗体、抗体药物偶联物、双特异性T细胞衔接器，以及BCMA靶向过继性细胞疗法如嵌合抗原受体（CAR）-T细胞。美国血液学会第63届年会更新了BCMA在MM中应用的部分信息。本综述总结了该会议上提出的部分相关要点。
With the gradual improvement of treatment regimens, the survival time of multiple myeloma (MM) patients has been significantly prolonged. Even so, MM is still a nightmare with an inferior prognosis. B-cell maturation antigen (BCMA) is highly expressed on the surface of malignant myeloma cells.
For the past few years, significant progress has been made in various BCMA-targeted immunotherapies for treating patients with RRMM, including anti-BCMA mAbs, antibody-drug conjugates, bispecific T-cell engagers, and BCMA-targeted adoptive cell therapy like chimeric antigen receptor (CAR)-T cell. The 63rd annual meeting of the American Society of Hematology updated some information about the application of BCMA in MM. This review summarizes part of the related points presented at this conference.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
